TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02120716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Check-Up for Expectant Moms
Description: Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
Study: NCT02858349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: High-intensity walking exercise using bursts of concentrated effort alternated with recovery periods
Study: NCT03681951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3145095
Description: GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3145095
Description: GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3145095
Description: GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3145095
Description: GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).
Study: NCT04019548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrotomy tube placement
Description: placement of the PEG tube depends on arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrotomy tube placement
Description: placement of the PEG tube depends on arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Two therapeutic regimen allowed:~* Days 1 and 22 : cisplatin 100mg/m2 IV~* Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Two therapeutic regimen allowed:~* Days 1 and 22 : cisplatin 100mg/m2 IV~* Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT). The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT). The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.
Study: NCT03295656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Contrast-enhanced US imaging of the appendix
Study: NCT05488223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AGPI ω-3 (Triple Strength Fish Oil®)
Description: The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AGPI ω-3 + MUFA (avocado oil)
Description: AGPI ω-3 (0.9g) + MUFA (avocado oil) (0.9g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MUFA (avocado oil) (1.8g)
Description: MUFA (avocado oil) (1.8g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
Study: NCT02018835

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: cardiac echography transthoracic

Intervention type: DEVICE
Group type: OTHER
Intervention: cardiac echography transthoracic

Intervention type: DEVICE
Group type: OTHER
Intervention: cardiac echography transthoracic

Intervention type: DEVICE
Group type: OTHER
Intervention: cardiac echography transthoracic

Intervention type: DEVICE
Group type: OTHER
Intervention: cardiac echography transthoracic
Study: NCT01762722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reduction of inspired oxygen
Description: Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
Study: NCT04135417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV
Description: Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
Study: NCT03071926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: 20 mg, qw, first 6 weeks ,every 8 weeks
Study: NCT02046824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtra®, Sorin cellsaver
Description: when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C.A.T.S.®, Fresenius cellsaver
Description: when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPAT®, Haemonetics, cellsaver
Description: when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: no use of cell saver
Description: When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
Study: NCT01013285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study: NCT00915733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: 100 mg twice daily for at least 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel (Plavix)
Description: 150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel (Plavix)
Description: 150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19
Description: CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19\*2 (rs4244285, c. 681G\>A, p.P227P), and CYP2C19\*3 (rs4986893, c. 636G\>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19
Description: CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19\*2 (rs4244285, c. 681G\>A, p.P227P), and CYP2C19\*3 (rs4986893, c. 636G\>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin (Acetylsalicylic acid)
Description: aspirin 100 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin (Acetylsalicylic acid)
Description: aspirin 100 mg qd
Study: NCT03438851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch Platform™
Description: NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch Platform™
Description: NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
Study: NCT02843971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measurement with the Sensimed triggerfish Device
Study: NCT03294109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abdominal wall block with liposomal bupivicaine
Description: Abdominal wall block with liposomal bupivicaine
Study: NCT01794923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBU BID
Description: 10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID
Description: 10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBU TID
Description: 10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TID
Description: 10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
Study: NCT01881750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Training (PRT)
Description: 12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent Education Group (PEG)
Description: 12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
Study: NCT01505010

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal denervation
Description: Renal denervation in the intervention group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Renal denervation in the intervention group
Study: NCT01626703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminding call
Study: NCT04476056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified Nutritional Therapy
Description: Intensified nutritional therapy will begin in the hospital setting and comprises intake of a commercial oral nutritional supplement (Fortimel Compact 2.4, Nutricia) twice per day as well as personalized dietary counselling. After discharge, supplementation will be continued for at least 28 days and if necessary throughout the entire study duration. Likewise, dietary counselling will be provided throughout the entire study period based on the patient's individual need. Dietary counselling is provided either face-to-face during the follow-up visits or remotely via telephone between visits.
Study: NCT02024919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary administration of diltiazem
Study: NCT00051363

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active CPAP
Description: Nightly nasal continuous positive airway pressure (CPAP)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham CPAP
Description: Sham CPAP machine will be used for participants in the placebo group.
Study: NCT02024919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intracoronary injection of 5 mL saline
Study: NCT03131219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participant received weight-based dosages for 26 weeks during the Initial Evaluation Period. Participants received a loading dose on Day 1, followed by maintenance dosing on Day 15 and once every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing \< 20 kg.
Study: NCT02614573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoagucheckXSR Capillary INR measures
Description: We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.~If capillary INR is \<2 or \>3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (\> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.~If capillary INR is \> 4, then verification by venous measure and refer to general practitioner.
Study: NCT00979433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Description: Bubble CPAP will be delivered using Fischer \& Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional CPAP
Description: Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
Study: NCT04579965

Intervention type: DRUG
Group type: OTHER
Intervention: medical treatment of isthmocele
Description: comparison between different drugs

Intervention type: DRUG
Group type: OTHER
Intervention: medical treatment of isthmocele
Description: comparison between different drugs
Study: NCT00412971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hexvix
Description: Single installation, TURB

Intervention type: OTHER
Group type: OTHER
Intervention: Standard white light cystoscopy
Study: NCT02004548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metatinib Tromethamine
Study: NCT03057808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gestational weight gain intervention
Description: This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gestational weight gain intervention
Description: This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum weight loss intervention
Description: The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum weight loss intervention
Description: The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
Study: NCT03772353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib (SHR6390) is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole, a third-generation aromatase inhibitor, is the principal drug used in the treatment of postmenopausal patients with both early- and advanced-stage endocrine-responsive breast cancer (BC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer
Study: NCT03935503

Intervention type: PROCEDURE
Intervention: TEP
Description: By making a 2 cm incision under the umbilicus, skin subcutaneous tissues are passed through blunt dissections and the anterior fascia of the rectus muscle is exposed. An anterior rectus sheath with a scalpel is performed with a 15 mm incision. The rectus muscle is laterally lateralized and the balloon trocar or laparoscope itself is advanced from the midline to the symphysis pubis via the posterior rectus sheath. After the peritoneal cavity is dissected, a low pressure pneumoperitone 10 mm Hasson trocar or another 10 mm balloon caged trocar is advanced through the subumblic incision. 9-11 mmHg low pressure pneumoperitoneum is created to prevent the development of subcutaneous emphysema. For proper imaging, the patient should have complete muscle relaxation. The patient is given a position towards the light trandelenburg and non-hernia side.

Intervention type: PROCEDURE
Intervention: Lichtenstein repair
Description: After the inguinal incision, the skin and subcutaneous camper and scarpa tissues are passed and the external oblique aponeurosis is dissected in the direction of the extension of the fibers and the medial lateral edge of the rectus is dissected to the lateral inguinal ligament, then the spermatic cord is released and suspended.The spermatic cord is separated from the inguinal canal.~In indirect hernias, the hernia sac is dissected from the spermatic cord and rejected into the abdomen by high ligation. In direct hernia, the hernia sac is pushed in and the transverse fascia is sutured with 2-3 separe stitches.